Waisman Biomanufacturing News
-
Beyond the bench: Waisman-born clinical trials
AT A GLANCE: Clinical trials serve as the crucial bridge between groundbreaking laboratory research and the eventual approval of new treatments or interventions. At the Waisman Center, researchers like Albee Messing, VMD,…
-
Bridging the gap: How WB is helping to translate research from bench to bedside
By Emily Leclerc, Waisman Science Writer One of Carl Ross’s favorite stories is actually an account of one of his failures. In the early 2000s Ross, the former managing director of Waisman…
-
Waisman Biomanufacturing selects new managing director
After an extensive national search, Chris Bartley was recently selected as the new managing director of Waisman Biomanufacturing (WB). Bartley most recently served as the facility’s interim director.
-
A science trailblazer retires: Stem cell researcher James Thomson’s legacy changed the future of biology
James Thomson helped the scientific world turn its attention to the shape-shifting stem cells that give rise to all of the building blocks of complex living organisms, from skin and bone, to…
-
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug
Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach…
-
Waisman Biomanufacturing partners with Heat Biologics to manufacture COVID-19 vaccine
Waisman Biomanufacturing at the University of Wisconsin–Madison is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials. Phase 1 trials could begin in early…
-
Clinical trial for Ebola vaccine developed at UW–Madison underway in Japan
As of this week, a phase one clinical trial to test a potential new Ebola vaccine developed by researchers at the University of Wisconsin–Madison is underway in Japan. Fifteen healthy young men*…
-
UW-Madison biomanufacturer offers essential gene-transfer capacity
Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the…
-
Waisman Biomanufacturing helps bring UMass Medical School HIV vaccine to Phase I trial
Waisman Biomanufacturing has produced and helped bring to clinical trial a vaccine that aims to prevent infection by the human immunodeficiency virus (HIV), which causes AIDS. The vaccine was developed by researchers…
-
Waisman Biomanufacturing to be part of UW-Madison partnership in $20 million cell-based therapy center
Waisman Biomanufacturing and Waisman affiliate investigators Randolph Ashton and Krishanu Saha will be part of a new engineering research center that will develop transformative tools and technologies for the consistent, scalable and…
Browse News by Topic
-
50th Anniversary
-
Alzheimer’s Disease
-
Autism
-
Awards and Honors
-
Brain Imaging
-
Cerebral Palsy
-
Clinics
-
Down Syndrome
-
Epidemiology
-
Español
-
Fragile X Syndrome
-
Friends of the Waisman Center
-
Hearing Research News
-
Mental Health
-
Neurodegenerative
-
Outreach
-
Parkinson’s Disease
-
PKU
-
Research
-
Service
-
Speech & Language
-
Stem Cells
-
Training
-
UCEDD
-
Vision
-
Waisman Biomanufacturing